AIM: To evaluate clinical effects of semiretrobulbar injection of triamcinolone acetonide(TA)for the treatment of thyroid associated ophalmopathy.

METHODS: Totally 84 eyes of 46 cases with thyroid associated ophalmopathy were treated with semiretrobulbar injection of TA(40mg)with 20g/L Lidocaine(0.5 mL)for each eye once every three weeks for four times during one course of treatment. Then symptoms and signs of the patients were observed after 1 month, 3 months, 6 mouths.

RESULTS: Symptoms of 43 cases were improved significantly. In all cases, eyeball recession rate was 83.6%, the palpebral fissure width reduction was 85.2%, visual acuity improvement was 80.9%, eye movement, strabismus, and diplopia improvement was 80.5%, compared to those before the treatment.

CONCLUSION: The treatment of semiretrobulbar injection of TA for thyroid associated ophalmopathy is safe, effective and mild in side effect.